CMV Clinical Trial
Official title:
Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
The ability to distinguish allogeneic hematopoietic cell transplantation (allo-HCT)
recipients at risk for cytomegalovirus (CMV) reactivation from those who are not is central
for optimal CMV management strategies. Measuring this cell mediated immunity has been
proposed as a potent tool to predict those patients at highest risk of CMV reactivation and
disease. This study will evaluate the ability of the T-SPOT.CMV test to predict
Cytomegalovirus (CMV) reactivation in allogeneic hematopoietic cell transplantation
(allo-HCT) pediatric recipients.
Primary Objectives:
To evaluate feasibility of T-SPOT.CMV spot count test in allo-HCT pediatric recipients.
To evaluate association of T-SPOT.CMV spot count in the first sample collected after patient
has engrafted with subsequent CMV reactivation in allo-HCT pediatric recipients.
Secondary Objectives:
To evaluate the correlation between T-SPOT.CMV spot count in donors with subsequent recipient
CMV spot count.
To explore the relationship between recipient T-SPOT.CMV spot counts and subsequent CMV
infection related morbidity and treatment outcomes among pediatric all-HCT recipients.
T-SPOT response will be measured using the results from the T-SPOT.CMV blood test in both HCT
recipients and HCT donors.
A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to
transplant.
Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the
course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly
starting at day +120.
HCT recipient participant demographic and clinical characteristics will be collected at
enrollment. Additional clinical information will be abstracted from the HCT recipient
participants medical record during the study follow-up period. This will include information
related to transplant history and outcome, infections, antimicrobial exposure, chemotherapy,
and laboratory values related to infectious diseases and immunosuppression.
The feasibility of the T-SPOT.CMV spot count test will be evaluated once the first 30
participants enrolled on study reach day +90. If 75% of patients have at least 1 evaluable
samples after engraftment (> 75,000 per microtiter wells), we will proceed with enrollment.
If more >25% of patients have all their samples deemed not evaluable due to insufficient
mononuclear cell count (<75,000 per microtiter wells) the study will be stopped and concluded
as not feasible.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT04101136 -
Effect of Atorvastatin on Subclinical Atherosclerosis
|
N/A | |
| Recruiting |
NCT06001320 -
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip
|
Early Phase 1 | |
| Completed |
NCT01923766 -
Cytotoxic T Cells to Prevent Virus Infections
|
Phase 1 | |
| Not yet recruiting |
NCT05969743 -
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
|
Phase 2 | |
| Recruiting |
NCT01011712 -
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
|
||
| Recruiting |
NCT06034925 -
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
|
Phase 4 | |
| Completed |
NCT04840199 -
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
|
Phase 2 | |
| Terminated |
NCT03502161 -
Clinical Evaluation of the QuantiFERON CMV Assay
|
||
| Not yet recruiting |
NCT06211543 -
Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
|
||
| Recruiting |
NCT04056533 -
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
|
Phase 2 | |
| Not yet recruiting |
NCT04280380 -
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
|
||
| Active, not recruiting |
NCT03924219 -
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
|
||
| Not yet recruiting |
NCT06453460 -
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
|
Phase 2 | |
| Completed |
NCT02694484 -
Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant
|
N/A | |
| Recruiting |
NCT06011486 -
Expansion of Virus-Specific Lymphocytes for Cell Therapy
|
Phase 1 | |
| Recruiting |
NCT04017962 -
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
|
Phase 2 | |
| Enrolling by invitation |
NCT04392297 -
Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
|
||
| Completed |
NCT00872703 -
Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?
|
N/A | |
| Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
| Recruiting |
NCT05041426 -
Letermovir for CMV Prevention After Lung Transplantation
|
Phase 2 |